Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | GPR4 | P46093 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL441325 | 0.98 | KDM1A (0.33) | KDM1ACA1CA2SMYD3ENPP2 | |
| Hydrochloric Acid SCHEMBL441324 | 0.98 | KDM1A (0.33) | KDM1ACA1CA2SMYD3ENPP2 | |
| SCHEMBL12940206 | 0.91 | ALDH1A1 (0.34) | CA1CA2ENPP2ALDH1A1LRRK2 | |
| SCHEMBL27952180 | 0.86 | SMYD3 (0.33) | KDM1ACA1CA2SMYD3GPR4 | |
| SCHEMBL13275499 | 0.86 | SMYD3 (0.33) | KDM1ACA1CA2SMYD3GPR4 | |
| SCHEMBL19756335 | 0.84 | EPHX2 (0.33) | — | |
| SCHEMBL15490000 | 0.83 | CYP2C19 (0.38) | CA1CA2ENPP2ALDH1A1 | |
| SCHEMBL15490002 | 0.83 | CYP2C19 (0.41) | CA1CA2ALDH1A1 | |
| SCHEMBL21707308 | 0.82 | KDM1A (0.33) | KDM1ACA1CA2SMYD3 | |
| SCHEMBL17481119 | 0.81 | CYP2C19 (0.44) | CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | KDM1A 2146/4885CA1 4037/4885CA2 4489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.